Literature DB >> 19005751

Low penetrance breast cancer predisposition SNPs are site specific.

Niall Mcinerney1, Gabrielle Colleran, Andrew Rowan, Axel Walther, Ella Barclay, Sarah Spain, Angela M Jones, Stephen Tuohy, Catherine Curran, Nicola Miller, Michael Kerin, Ian Tomlinson, Elinor Sawyer.   

Abstract

Large scale association studies have identified low penetrance susceptibility alleles that predispose to breast cancer. A locus on chromosome 8q24.21 has been shown to harbour variants that predispose to breast, ovarian, colorectal and prostate cancer. The finding of risk variants clustering at 8q24 suggests that there may be common susceptibility alleles that predispose to more than one epithelial cancer. The aim of this study was firstly to determine whether previously identified breast cancer susceptibility alleles are associated with sporadic breast cancer in the West of Ireland and secondly to ascertain whether there are susceptibility alleles that predispose to all three common epithelial cancers (breast, prostate, colon). We genotyped a panel of 24 SNPs that have recently been shown to predispose to prostate, colorectal or breast cancer in 988 sporadic breast cancer cases and 1,016 controls from the West of Ireland. We then combined our data with publicly available datasets using standard techniques of meta-analysis. The known breast cancer SNPs rs13281615, rs2981582 and rs3803662 were confirmed as associated with breast cancer risk (P (allelic test) = 1.8 x 10(-2), OR = 1.17; P (allelic test) = 2.2 x 10(-3), OR = 1.22; P (allelic test) = 5.1 x 10(-2), OR = 1.15, respectively) in the West of Ireland cohort. For the remaining five breast cancer SNPs that were studied there was no evidence of an association with breast cancer in the West Ireland population (P (allelic test) > 6.5 x 10(-2)). There was also no association between any of the prostate or colorectal susceptibility SNPs, whether at 8q24 or elsewhere, with breast cancer risk. Meta-analysis confirmed that all susceptibility SNPs were site specific, with the exception of rs6983269 which is known to predispose to both colorectal and prostate cancer. This study confirms that susceptibility loci at FGFR2, 8q24 and TNCR9 predispose to sporadic breast cancer in the West of Ireland. It also suggests that low penetrance susceptibility SNPs for breast, prostate and colorectal cancer are distinct. Although 8q24 harbours variants that predispose to all three cancers, the susceptibility loci within the region appear to be specific for the different cancer types with the exception of rs6983269 in colon and prostate cancer.

Entities:  

Mesh:

Year:  2008        PMID: 19005751     DOI: 10.1007/s10549-008-0235-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  21 in total

1.  Association of 8q24 rs13281615A > G polymorphism with breast cancer risk: evidence from 40,762 cases and 50,380 controls.

Authors:  Guiping Dai; Zijian Guo; Xiaojing Yang; Bo Yu; Lihua Li
Journal:  Mol Biol Rep       Date:  2013-01-05       Impact factor: 2.316

2.  Polymorphism of 8q24 rsl3281615 and breast cancer risk : a meta-analysis.

Authors:  Yan-Lei Pei; He-Long Zhang; Hong-Guang Han
Journal:  Tumour Biol       Date:  2012-11-07

3.  Association between polymorphisms within the susceptibility region 8q24 and breast cancer in a Chinese population.

Authors:  Yu Zhang; Pengfei Yi; Wei Chen; Jie Ming; Beibei Zhu; Zhi Li; Na Shen; Wei Shi; Juntao Ke; Qunzi Zhao; Xuzai Lu; Xueqiong Xun; Li Liu; Ranran Song; Hui Guo; Rong Zhong; Liming Liang; Tao Huang; Xiaoping Miao
Journal:  Tumour Biol       Date:  2014-01-11

4.  Association of genetic polymorphisms in cell-cycle control genes and susceptibility to endometrial cancer among Chinese women.

Authors:  Hui Cai; Yong-Bing Xiang; Shimian Qu; Jirong Long; Qiuyin Cai; Jing Gao; Wei Zheng; Xiao Ou Shu
Journal:  Am J Epidemiol       Date:  2011-03-31       Impact factor: 4.897

5.  FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors.

Authors:  Catalin Marian; Heather M Ochs-Balcom; Jing Nie; Bhaskar V Kallakury; Christine B Ambrosone; Maurizio Trevisan; Stephen Edge; Peter G Shields; Jo L Freudenheim
Journal:  Int J Cancer       Date:  2010-11-12       Impact factor: 7.396

6.  rs2981582 is associated with FGFR2 expression in normal breast.

Authors:  Chang Sun; Olufunmilayo I Olopade; Anna Di Rienzo
Journal:  Cancer Genet Cytogenet       Date:  2010-03

7.  Association of TGF-β1 -509C/T polymorphisms with breast cancer risk: evidence from an updated meta-analysis.

Authors:  Yadong Wang; Xinwei Chu; Xiaojing Meng; Fei Zou
Journal:  Tumour Biol       Date:  2013-08-28

8.  11q13 is a susceptibility locus for hormone receptor positive breast cancer.

Authors:  Diether Lambrechts; Therese Truong; Christina Justenhoven; Manjeet K Humphreys; Jean Wang; John L Hopper; Gillian S Dite; Carmel Apicella; Melissa C Southey; Marjanka K Schmidt; Annegien Broeks; Sten Cornelissen; Richard van Hien; Elinor Sawyer; Ian Tomlinson; Michael Kerin; Nicola Miller; Roger L Milne; M Pilar Zamora; José Ignacio Arias Pérez; Javier Benítez; Ute Hamann; Yon-Dschun Ko; Thomas Brüning; Jenny Chang-Claude; Ursel Eilber; Rebecca Hein; Stefan Nickels; Dieter Flesch-Janys; Shan Wang-Gohrke; Esther M John; Alexander Miron; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Georgia Chenevix-Trench; Jonathan Beesley; Xiaoqing Chen; Florence Menegaux; Emilie Cordina-Duverger; Chen-Yang Shen; Jyh-Cherng Yu; Pei-Ei Wu; Ming-Feng Hou; Irene L Andrulis; Teresa Selander; Gord Glendon; Anna Marie Mulligan; Hoda Anton-Culver; Argyrios Ziogas; Kenneth R Muir; Artitaya Lophatananon; Suthee Rattanamongkongul; Puttisak Puttawibul; Michael Jones; Nicholas Orr; Alan Ashworth; Anthony Swerdlow; Gianluca Severi; Laura Baglietto; Graham Giles; Melissa Southey; Federik Marmé; Andreas Schneeweiss; Christof Sohn; Barbara Burwinkel; Betul T Yesilyurt; Patrick Neven; Robert Paridaens; Hans Wildiers; Hermann Brenner; Heiko Müller; Volker Arndt; Christa Stegmaier; Alfons Meindl; Sarah Schott; Claus R Bartram; Rita K Schmutzler; Angela Cox; Ian W Brock; Graeme Elliott; Simon S Cross; Peter A Fasching; Ruediger Schulz-Wendtland; Arif B Ekici; Matthias W Beckmann; Olivia Fletcher; Nichola Johnson; Isabel Dos Santos Silva; Julian Peto; Heli Nevanlinna; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Thilo Dörk; Peter Schürmann; Michael Bremer; Peter Hillemanns; Natalia V Bogdanova; Natalia N Antonenkova; Yuri I Rogov; Johann H Karstens; Elza Khusnutdinova; Marina Bermisheva; Darya Prokofieva; Shamil Gancev; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska; Katarzyna Durda; Børge G Nordestgaard; Stig E Bojesen; Charlotte Lanng; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Loris Bernard; Fergus J Couch; Janet E Olson; Xianshu Wang; Zachary Fredericksen; Grethe Grenaker Alnaes; Vessela Kristensen; Anne-Lise Børresen-Dale; Peter Devilee; Robert A E M Tollenaar; Caroline M Seynaeve; Maartje J Hooning; Montserrat García-Closas; Stephen J Chanock; Jolanta Lissowska; Mark E Sherman; Per Hall; Jianjun Liu; Kamila Czene; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Annika Lindblom; Sara Margolin; Alison M Dunning; Paul D P Pharoah; Douglas F Easton; Pascal Guénel; Hiltrud Brauch
Journal:  Hum Mutat       Date:  2012-04-30       Impact factor: 4.878

9.  Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases.

Authors:  Wen-Feng Gong; Jian-Hong Zhong; Bang-De Xiang; Liang Ma; Xue-Mei You; Qiu-Ming Zhang; Le-Qun Li
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

10.  The risk allele of SNP rs3803662 and the mRNA level of its closest genes TOX3 and LOC643714 predict adverse outcome for breast cancer patients.

Authors:  Eydis Th Gudmundsdottir; Rosa B Barkardottir; Adalgeir Arason; Haukur Gunnarsson; Laufey Th Amundadottir; Bjarni A Agnarsson; Oskar Th Johannsson; Inga Reynisdottir
Journal:  BMC Cancer       Date:  2012-12-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.